Premium
Latent membrane protein 2A inhibits expression level of Smad2 through regulating miR‐155‐5p in EBV‐associated gastric cancer cell lines
Author(s) -
Shi Qianzhu,
Zhang Yan,
Liu Wen,
Xiao Hua,
Qi Yifan,
Li Jun,
Luo Bing
Publication year - 2020
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.25579
Subject(s) - gene knockdown , signal transduction , cancer research , apoptosis , cell cycle , biology , western blot , epstein–barr virus , cancer , cell cycle checkpoint , cell growth , microbiology and biotechnology , virus , virology , gene , genetics
Epstein‐Barr virus (EBV) infection is one of the causes of gastric cancer (GC). Besides, previous studies have demonstrated that EBV‐encoded latent membrane protein 2A (LMP2A) influences the pathogenesis of EBV‐associated gastric cancer (EBVaGC) through regulating several key pathways. In this study, the expression level of Smad2 was observed, which was reduced in EBVaGC cell lines, especially in the presence of LMP2A. Meanwhile, we found that LMP2A promoted the expression of miR‐155‐5p by activated nuclear factor‐κB (NF‐κB) signaling. After being treated with NF‐κB inhibitor (BAY 11‐7082), miR‐155‐5p sharply decreased. Western blot analysis proved that the overexpression of miR‐155‐5p could inhibit Smad2. Functional studies showed that the role of miR‐155‐5p might lead to good prognosis in EBV‐positive GC through promoting cell apoptosis and cell cycle arrest, as well as inhibiting tumor proliferation. In addition, p‐Smad2 protein was also reduced or induced by overexpression or knockdown, respectively, of miR‐155‐5p. Immunofluorescence analysis further indicated that LMP2A prevented p‐Smad2 from transferring to the nucleus, which played a crucial role in transforming growth factor‐β (TGF‐β) signaling. In summary, our findings confirmed the relationship between LMP2A and Smad2 and provided a potential regulation of the TGF‐β pathway in EBVaGC.